Advances in Economics, Management and Political Sciences
- The Open Access Proceedings Series for Conferences
Proceedings of the 7th International Conference on Economic Management and Green Development
Series Vol. 28 , 10 November 2023
Open
Access | Article
Medical Industry Analysis Post-Pandemic from the Year 2020 to 2021
* Author to whom correspondence should be addressed.
Abstract
This article collects data on the medical industry for 2020-2021 and explores various indicators that may affect the earnings of medical head companies. The categories of pharmaceutical companies are divided into Bioengineering, Medical Services, and Pharmaceuticals. According to the linear regression model, the R-squared and adjusted R-squared values are large and close to 1. It indicates that our data selection is relevant, and our independent variables can be used as predictors of the dependent variable. Differences in the percentage change in assets, the related industries of individual companies, and the number of employees can be strong predictors of changes in their revenue ratios.
Keywords
Medical Industry, Linear Regression, COVID-19
References
1. Lavassani K M, Movahedi B, Iyengar R J. Multi-layer, multi-tier analysis of global supply chain in medical equipment sector: network science application[J]. Transnational Corporations Review, 2022, 14.
2. Baghbanian A, Safdari R, Erfannia L , et al. The Medical Tourism Industry in Iran: A Review of Websites Designed for Cross-border Patients[J]. Health Scope, 2021:108482.
3. Yadav R, Murria S, Sharma A. A research review on semantic interoperability issues in electronic health record systems in medical healthcare[M]. 2021.
4. Bogdanova M P. Problems And Prospects Of Digital Transformation Of Medical Industry Enterprises[J]. Business Strategies, 2021.
5. Yang H S. A study on Medical Device Security Status in Medical Convergence Industry[C]// 2021 21st ACIS International Winter Conference on Software Engineering, Artificial Intelligence, Networking and Parallel/Distributed Computing (SNPD-Winter). 2021.
6. Committee composition. 3M. (n.d.). Retrieved December 22, 2022, from https://investors.3m.com/governance/committee-composition/default.aspx
7. Alkermes revenue 2010-2022: Alks. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/ALKS/alkermes/revenue
8. Amgen Gross Profit 2010-2022: AMGN. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/AMGN/amgen/gross-profit
9. Biogen revenue 2010-2022: BIIB. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/BIIB/biogen/revenue
10. BioMarin Pharmaceutical Gross Profit 2010-2022: BMRN. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/BMRN/biomarin-pharmaceutical/gross-profit
11. Edwards Lifesciences revenue 2010-2022: EW. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/EW/edwards-lifesciences/revenue
12. Gilead Sciences Revenue 2010-2022: Gild. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/GILD/gilead-sciences/revenue
13. Illumina revenue 2010-2022: ILMN. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/ILMN/illumina/Revenue
14. Incyte revenue 2010-2022: Incy. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/INCY/incyte/revenue
15. Merck gross profit 2010-2022: MRK. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/MRK/merck/gross-profit
16. Mirati Therapeutics Revenue 2010-2022: MRTX. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/MRTX/mirati-therapeutics/revenue
17. Moderna Revenue 2017-2022: Mrna. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/MRNA/moderna/revenue
18. Regeneron Pharmaceuticals revenue 2010-2022: REGN. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/REGN/regeneron-pharmaceuticals/revenue
19. Seagen gross profit 2010-2022: SGEN. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/SGEN/seagen/gross-profit
20. Vertex Pharmaceuticals Gross Profit 2010-2022: VRTX. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/VRTX/vertex-pharmaceuticals/gross-profit
21. Agilent Technologies Gross Profit 2010-2022: A. Macrotrends. (n.d.). Retrieved December 22, 2022, from https://www.macrotrends.net/stocks/charts/A/agilent-technologies/gross-profit
22. Our leaders. AbbVie. (n.d.). Retrieved December 22, 2022, from https://www.abbvie.com/our-company/leadership.html
23. GE Board of Directors. General Electric. (n.d.). Retrieved December 22, 2022, from https://www.ge.com/investor-relations/governance
24. Baxter International: Bax - Assets. TRADING ECONOMICS. (n.d.). Retrieved December 22, 2022, from https://tradingeconomics.com/bax:us:assets
25. Roche Holding: Retrieved December 22, 2022 from https://www.roche.com/investors/reports/
26. BRISTOL-MYERS SQUIBB: Retrieved December 22, 2022 from https://www.roche.com/investors/reports/
27. Sanofi: Retrieved December 22, 2022 from https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2021
28. AstraZeneca: Retrieved December 22, 2022 from https://www.astrazeneca.com/investor-relations/
29. GSK: Retrieved December 22, 2022 from https://www.gsk.com/en-gb/investors/financial-reports/
30. Lilly Eli: Retrieved December 22, 2022 from https://www.lilly.com/policies-reports/year-in-review
31. Amgen: Retrieved December 22, 2022 from https://investors.amgen.com/financials/annual-reports
32. Moderna: Retrieved December 22, 2022 from https://investors.modernatx.com/financials/annual-reports/default.aspx
33. Bayer AG-REG: Retrieved December 22, 2022 from https://www.bayer.com/en/investors/integrated-annual-reports
34. Viatris: Retrieved December 22, 2022 from https://investor.viatris.com/financial-and-filings/sec-filings
35. Regeneron: Retrieved December 22, 2022 from https://investor.regeneron.com/
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 7th International Conference on Economic Management and Green Development
- ISBN (Print)
- 978-1-83558-077-6
- ISBN (Online)
- 978-1-83558-078-3
- Published Date
- 10 November 2023
- Series
- Advances in Economics, Management and Political Sciences
- ISSN (Print)
- 2754-1169
- ISSN (Online)
- 2754-1177
- DOI
- 10.54254/2754-1169/28/20231293
- Copyright
- 10 November 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited